恩替卡韦联合苦参素治疗HBeAg阳性慢性乙型肝炎的疗效分析

Effect analysis of Entecavir combined with Oxymatrine on patients with HBeAg positive chronic hepatitis B

目的观察恩替卡韦(ETV)联合苦参素治疗HBeAg阳性慢性乙型肝炎(CHB)的疗效。方法 120例HBeAg阳性CHB患者随机分为2组,治疗组60例,ETV 0.5 mg每天1次口服,苦参素胶囊0.2 g/次、3次/d口服;对照组60例,ETV 0.5 mg/次、1次/d口服。观察ALT、HBV-DNA、HBeAg/HBeAb指标,在服药12、24、48周时的结果。结果①治疗组和对照组在12、24周的ALT复常率分别为60.00%、75.00%和48.33%、60.55%,疗效无差异(P>0.05);治疗组和对照组在48周的ALT复常率分别为91.67%和76.67%,差异有统计学意义(P<0.05);②治疗组和对照组在12、24周的HBV DNA阴转率分别为40.00%、61.67%和38.33%、51.67%,结果无差异(P>0.05);治疗组和对照组在48周的HBV DNA阴转率分别为81.67%和61.67%,差异有统计学意义(P<0.05);③治疗组和对照组在12、24周HBeAg/HBeAb血清转换率11.67%、18.33%和10.00%、15.00%,差异无统计学意义(P>0.05);治疗组和对照组在48周HBeAg/HBeAb血清转换率35.00%和18.33%,差异有统计学意义(P<0.05)。结论 ETV联合苦参素治疗CHB可明显提高抗病毒治疗效果。

Objective To observe the effects of Entecavir combined with oxymatrine on patients with HBeAg-positive chronic hepatitis B （CHB）. Methods 120 cases were enrolled with HBeAg-positive CHB. They were randomly divided into treatment group （60 cases） and control group （60 cases）, patients in treatment group daily received Entecavir 0.5 rag, Oxy- matrine tablets 0.6 g and those in control group daily doses Entecavir 0.5 mg. Therapeutic effects were observed at 12, 24, 48 weeks after medication. Results （1） The ALT normalization rates of control group and treatment group after 12, 24, 48 weeks were 60.00%, 75.00%, 91.67% and 48.33%, 60.55%, 76.67%, respectively, and in the 12, 24 weeks, no statistically difference was found between two groups （P 〉 0.05）, while in 48 weeks there was difference between them （P 〈 0.05）.（ 2） The HBV-DNA negative conversion rates in control group and treatment group after 12, 24, 48 weeks were 40.00%, 61.67%, 81.67% and 38.33%, 51.67%, 61.67%, respectively, and in the 12, 24 weeks, no statistically significant difference was found between two groups （P 〉 0.05）, while in 48 weeks there was difference between them （P 〈 0.05）. （3）The HBeAg / HBeAb seroconversion rate of control group and treatment group in 12 weeks and 24 weeks were respectively 11.67%, 18.33% and 10.00%, 15.00% （P 〉 0.05）, while in 48 weeks, respectively 35.00% and 18.33%. The differences were also statistically significant （P 〈 0.05）. Conclusion The combination of Entecavir and Oxymatrine can significantly enhance the effectiveness of antiviral therapy in the treatment of CHB.